Beijing Tongrentang Technologies Co Ltd (HK: 01666) has announced its interim results for the six months ended June 30, 2026, revealing a 19.1% decline in revenue to RMB3.024 billion. The company's net profit attributable to shareholders fell by 26.43% year-on-year to RMB249 million, with earnings per share reaching RMB0.19.

During the reporting period, the group adhered to its overarching principle of steady progress, implementing a working approach centered on transforming mindsets, enhancing coordination, improving quality and efficiency, strengthening execution, prioritizing management, and building confidence. The company maintained its focus on the core business of proprietary Chinese medicines, continuing to advance marketing system reforms and optimize production operations.

The decline in performance for the period was attributed to changes in the industry landscape, adjustments in market demand, and the group's proactive optimization of its channel management strategies. Despite these challenges, the company has persistently pursued initiatives aimed at developing core product varieties, refining its product mix, and raising operational effectiveness. These strategic measures have been implemented steadily, keeping the foundation of its core business stable and positioning the group for long-term, sustainable growth.